Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
BMC Vet Res ; 8: 195, 2012 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-23082892

RESUMEN

BACKGROUND: Components of the extracellular matrix have been studied in an attempt to elucidate the mechanisms involved in the biological behaviour of tumours. The presence of the proteoglycan versican has been strongly associated with cancer development and progression. However, relationship between versican expression and clinical pathological factors and overall survival has not been previously studied in veterinary medicine. Carcinomas in benign mixed tumours (CBMTs) are one of the most common malignant tumours in female canines and can serve as models for studies of tumour progression. The aim of this study was to evaluate the expression of versican in in situ and invasive carcinomatous areas of canine CBMTs and to evaluate possible associations of versican expression with other classic prognostic factors and overall survival. RESULTS: Clinical staging; histological grade determination; immunohistochemical staining for versican, E-cadherin and Ki-67; and confirmation of invasion areas by staining for p63 and smooth muscle α-actin (α-SMA) were performed on 49 canine cases of CBMT. Tumour invasion was considered when suspicious Haematoxylin-Eosin (HE)-stained areas showed a total loss of α-SMA and p63 immunoreactivity. Versican immunoreactivity was less intense in the areas adjacent to the in situ carcinomatous regions, compared to invasive regions, which showed extensive and strong staining. CONCLUSIONS: Our data reveal that in canine CBMTs, versican expression differs significantly between invasive and in situ areas, suggesting a role for this molecule in tumour progression. Although a direct relationship exists between versican and invasiveness, our results indicate that the isolated evaluation of this proteoglycan does not represent an independent prognostic factor in canine CBMTs.


Asunto(s)
Carcinoma/metabolismo , Enfermedades de los Perros/metabolismo , Regulación Neoplásica de la Expresión Génica/fisiología , Neoplasias Mamarias Animales/patología , Versicanos/metabolismo , Animales , Adhesión Celular , Proliferación Celular , Perros , Femenino , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/veterinaria , Ganglios Linfáticos/patología , Masculino , Neoplasias Mamarias Animales/metabolismo , Invasividad Neoplásica , Versicanos/genética
2.
Vet J ; 200(1): 146-51, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24582132

RESUMEN

The matrix of canine mixed mammary tumors (CMMTs) consists of proliferating spindle cells of possible myoepithelial origin, as well as myxomatous tissue, cartilage matrix and/or bone. Among the multiple components of this tumor extracellular matrix, versican probably plays a prominent role due to its importance in tumor progression, cell proliferation and differentiation. However, there are few data related to a possible association between versican expression and the state of myoepithelial cell differentiation in CMMTs. Using immunohistochemistry and histochemistry, the objective of this study was to evaluate the expression of versican, sulfated proteoglycans and mucopolysaccharides in myoepithelial cells at different stages of differentiation and to explore a potential relationship with p63 and α-smooth muscle actin (SMA) expression. A significant difference in versican expression was observed among the different stages of myoepithelial cell differentiation with an inverse correlation between versican and p63/SMA expression. These results suggest that at an early stage of proliferation, myoepithelial cells acquire a phenotype consistent with a role in chondrogenesis. Moreover, myoepithelial cells showed an affinity for safranin and periodic acid-Schiff staining at different stages of proliferation supporting the myoepithelial origin of spindle cells from CMMTs.


Asunto(s)
Proteoglicanos Tipo Condroitín Sulfato/genética , Enfermedades de los Perros/metabolismo , Glicosaminoglicanos/genética , Neoplasias Mamarias Animales/patología , Mioepitelioma/metabolismo , Versicanos/genética , Actinas/metabolismo , Animales , Diferenciación Celular , Proteoglicanos Tipo Condroitín Sulfato/metabolismo , Perros , Células Epiteliales , Femenino , Expresión Génica , Glicosaminoglicanos/metabolismo , Inmunohistoquímica , Neoplasias Mamarias Animales/metabolismo , Fosfoproteínas/metabolismo , Versicanos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA